C Diff Drug Development

According to the report published by Virtue Market Research in Global Microbiome Therapeutics for Clostridium Difficile Infection Market was valued at USD 1 2 billion and is projected to reach a market size of USD 3 75 billion by the ...

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

Acurx Pharmaceuticals, Inc. today announced three scientific posters were presented during the 13th International Conference on Molecular Biology and Pathogenesis of Clostridia (ClostPath) held in Banff, Canada from September 19 to 23, 2023.

Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.

The discovery of compound 57, a new, totally synthetic 1,2,4-oxadiazole antibacterial agent, is described. This oxadiazole displays highly selective, bactericidal killing of Clostridioides (Clostridium) difficile, the bacterium that causes C. difficile infection (CDI) in both ho …

CAMBRIDGE, Mass., October 11, 2023--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the details of two poster presentations at IDWeek 2023, being held virtually and in person in Boston, MA on October 11-15. The analyses cover two defined bacterial consortium candidates and include additional results from the VE303 Phase 2 CONSORTIUM study and an assessment of VE707 for the prevention

PRINCETON, N.J., October 11, 2023--Kanvas Biosciences, the leader in microbiome mapping technology, today announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition transitions Kanvas Biosciences from a technology company with a transformative spatial biology platform to a full-stack therapeutics company with active clinical programs and a new cell banking fac

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection - read this article along with other careers information, tips and advice on BioSpace

On 5 October 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of

Thiopeptides exhibit potent antimicrobial activity against Gram-positive pathogens by inhibiting bacterial protein synthesis. Micrococcins are among the structurally simpler thiopeptides, but they have not been exploited in detail. This research involved a computational simulation of micrococcin P2 …

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical …

Clostridioides difficile causes life-threatening diarrhea and is the leading cause of healthcare associated bacterial infections in the United States. During infection, C. difficile releases the gut-damaging toxins, TcdA and TcdB, the primary determinants of disease pathogenesis and ar …

Acurx Pharmaceuticals has completed a Phase IIb trial of its antibiotic candidate ibezapolstat to treat Clostridioides difficile infection.

Stickland-fermenting Clostridia preferentially ferment amino acids to generate energy and anabolic substrates for growth. In gut ecosystems, these species prefer dual redox substrates, particularly mucin-abundant leucine. Here, we establish how theronine, a more prevalent, mucin-abundant subs …

Based on positive Phase II data, first-in-class antibiotic candidate ibezapolstat for C. difficile is expected to advance to Phase III sooner.

Molecular mimicry, a phenomenon in which microbial or environmental antigens resemble host antigens, has been proposed as a potential trigger for autoimmune responses. In this study, we employed a bioinformatics approach to investigate the role of molecular mimicry in Clostridioides difficile …

Envenomation by the Trinidad thick-tailed scorpion Tityus trinitatis may result in fatal myocarditis and there is a high incidence of acute pancreatitis among survivors. Peptidomic analysis (reversed-phase HPLC followed by MALDI-TOF mass spectrometry and automated Edman degradation) of T. …

The research report on the global "C. difficile Infection Therapeutic Drug Market" for 2023 includes an overview of the market, market dynamics, segmentation (by type, application, end user, and region), the most recent

The intestinal pathogen Clostridioides difficile is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis in humans. The symptoms of C. difficile-associated diseases (CDADs) are directly associated with the pathogen's toxins TcdA and TcdB, which enter host ce …

"Clostridium Difficile Infections Market"DelveInsight's "Clostridium Difficile Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Clostridium Difficile

The antibody screening platform described here simplifies the neutralizing antibody discovery procedure and will be an attractive alternative for screening functional antibodies against infectious diseases.

npj Antimicrobials and Resistance - Using next generation antimicrobials to target the mechanisms of infection

Clostridioides difficile is an anaerobic Gram-positive bacterium that colonizes the gut of patients treated with broad-spectrum antibiotics. The normal gut microflora prevents C. difficile colonization; however, dysbiosis by treatment with broad-spectrum antibiotics causes recur …

Our findings, demonstrating in vivo efficacy of ADS024 in protecting against CDI challenge in mouse models, support the use of ADS024 in preventing recurrent CDI following standard antibiotic treatment.

Our findings, demonstrating in vivo efficacy of ADS024 in protecting against CDI challenge in mouse models, support the use of ADS024 in preventing recurrent CDI following standard antibiotic treatment.

[122 Pages Report] "C. difficile Infection Therapeutic Drug Market" Market Size, Share and Industry Trends Analysis Report By Applications (Hospital, Clinic),Types (metronidazole, vancomycin, fidaxomicin, bezlotoxumab.),

The cytoplasmic steps of peptidoglycan synthesis represent an important targeted pathway for development of new antibiotics. Herein, we report the synthesis of novel 3-oxopyrazolidin-4-carboxamide derivatives with variable amide side chains as potential antibacterial agents targeting MurA enzyme, th …

"C. difficile Infection Therapeutic Drug Market" Size, Share, Growth Report 2023-2030 | | No. of pages: 107 Report which offers an in-depth analysis Grounded on Applications (Hospital, Clinic), and Types

Clostridioides difficile infection (CDI) is a major identifiable cause of antibiotic-associated diarrhea. In our previous study (J. Med. Chem., 2018, 61, 6759-6778), we have identified N-phenyl-cholan-24-amide as a potent inhibitor of spore germination. The most potent compounds in our previous work …